Breathe Well Live Well
|
Array says asthma drug improves lung function in study, seeks partner for …
MedCity News (Reuters) – Array Biopharma Inc said one of its drugs met the main goal of improving lung function in a mid-stage study among patients with mild to moderate persistent allergic asthma. Array shares rose as much as 19 percent to $6.64 — their highest … |
View full post on asthma – Google News
UPI.com |
Lung expert: Written action plan needed for child with asthma
UPI.com BETHESDA, Md., July 23 (UPI) — A written action plan for a healthcare provider and anyone who cares for a child with asthma is essential, a U.S. lung expert recommends. Dr. James Kiley, a lung diseases expert at the National Institutes of Health in … |
View full post on asthma – Google News
|
Array Biopharma's new asthma drug meets goal of improved lung function
Denver Post Array Biopharma Inc. said Tuesday, one of its drugs met the main goal of improving lung function in a mid-stage study among patients with mild to moderate persistent allergic asthma. Array shares rose 12.7 percent, or 71 cents, to $6.27 in morning … Array BioPharma: Study Shows Asthma Candidate ARRY-502 Improves Lung … Array BioPharma scores midstage success for asthma drug Array Shares Climb After Asthma Drug Shows Positive Phase 2 Results |
View full post on asthma – Google News
|
Array BioPharma: Study Shows Asthma Candidate ARRY-502 Improves Lung …
Wall Street Journal Secondary efficacy endpoints in the proof-of-concept study were also achieved, including reduced short-acting beta agonist use; asthma control; forced vital capacity improvement; symptom-free days during treatment; and improvement in rhinasthma and … Array BioPharma: ARRY-502 Meets Primary And Secondary Endpoints In … Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial |
View full post on asthma – Google News
| Related Articles |
Differences in serial lung function recorded on four data-logging meters.
J Asthma. 2013 Jul 19;
Authors: Adeniyi BO, Moore CV, Erhabor GE, Burge S
Abstract
Abstract Introduction Lung function measurements performed several times daily are useful for the diagnosis of occupational asthma. Patient fabrication of hand-recorded charts can limit confidence in the results; this is overcome using electronic meters that log time and measurement. We have compared individual and meter differences in FEV1 and PEF recorded by hand and from meter logs using expert subjects on 4 data-logging spirometers with different methods of measurement and different quality control software. Method Eight workers in a respiratory physiology department were asked to record FEV1 and PEF 2-hourly from waking for 7 days using 4 electronic meters (Easyone, Micro DL, Vitalograph Diary card 2110 and Piko-1) in random order. Subjects hand-recorded the best FEV1 and PEF from each session, this was compared with the logged data. Results Discordant measurements from individuals were lower for FEV1 than PEF and differed from 4.4-19.1% for FEV1 (mean 9.4%, p<0.0001) and 6-23.3% for PEF (mean 12.6, p<0.0001). There were also significant differences between meters for both variables (p<0.0001). The magnitude of the differences in PEF was highest for the Easyone (34 litres/min) and lowest for the Vitalograph Diary card 2110 (14 litres/min) and varied significantly between meters (mean 22 L/min, p=0.002). Conclusion Differences between hand-recorded and logged measurements are unlikely to be due solely to patient fabrication and can be due to quality criteria or other unclear software requirements applied after the results are shown on the meter screen; they differ between meters. Whether the differences shown affect clinical outcome will require further investigation.
PMID: 23865815 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
| Related Articles |
Group 2 innate lymphoid cells in lung inflammation.
Immunology. 2013 Jul 19;
Authors: Li BW, Hendriks RW
Abstract
Although allergic asthma is a heterogeneous disease, allergen-specific T helper 2 (Th2) cells producing the key cytokines involved in type 2 inflammation, IL-4, IL-5 and IL-13, are thought to play a major role in asthma pathogenesis. This model is challenged by the recent discovery of group 2 innate lymphoid cells (ILC2) that represent a critical innate source of type 2 cytokines. These ILC2 are activated by epithelial cell-derived cytokines, including IL-25 and IL-33, which have been implicated in the initiation of asthma. In this review, we will discuss recent studies supporting a significant role for ILC2 in lung inflammation, with special attention to allergen-induced asthma. This article is protected by copyright. All rights reserved.
PMID: 23866009 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
|
American Lung Association to host asthma camp
The Inter-Mountain The American Lung Association in West Virginia and United Hospital Center are now accepting applications for Camp Catch Your Breath. Designed for children with asthma, the camp will be held July 21-26 at Jackson's Mill Conference Center in Weston. |
View full post on asthma – Google News
Mirror.co.uk |
New asthma test can also detect lung cancer
Mirror.co.uk A simple breath test used to monitor asthma can detect lung cancer, doctors trying out the device have found. Medics stumbled across the early-warning sign during trials in Bangladesh where they spotted two patients with early stages of the killer disease. |
View full post on asthma – Google News
The rabbit as a model for studying lung disease and stem cell therapy.
Biomed Res Int. 2013;2013:691830
Authors: Kamaruzaman NA, Kardia E, Kamaldin N’, Latahir AZ, Yahaya BH
Abstract
No single animal model can reproduce all of the human features of both acute and chronic lung diseases. However, the rabbit is a reliable model and clinically relevant facsimile of human disease. The similarities between rabbits and humans in terms of airway anatomy and responses to inflammatory mediators highlight the value of this species in the investigation of lung disease pathophysiology and in the development of therapeutic agents. The inflammatory responses shown by the rabbit model, especially in the case of asthma, are comparable with those that occur in humans. The allergic rabbit model has been used extensively in drug screening tests, and this model and humans appear to be sensitive to similar drugs. In addition, recent studies have shown that the rabbit serves as a good platform for cell delivery for the purpose of stem-cell-based therapy.
PMID: 23653896 [PubMed – in process]
View full post on pubmed: asthma
|
Trial asthma drug targets lung inflammation – Medical Xpress
Medical Xpress Speaking in the lead up to World Asthma Day (7 May), respiratory health expert Associate Professor Sandra Hodge (University of Adelaide School of Medicine and Royal Adelaide Hospital) says the trial treatment is aimed at helping asthma sufferers who … |
View full post on asthma – Google News